HPTN 084:


A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

Jennifer Farrior

29 September 2023 HPTN Regional Meeting Cape Town, SA







HPTN 084: Protocol History



Version 1.0 2 March 2017

Double Blinded Randomized to Product

Version 3.0 12 August 2021

OLE 1
Product Choice

Version 2.0 6 November 2019

LARC required

Version 4.0 2 November 2022

OLE 2
Extended CAB LA access



HPTN 084: Protocol Version 5



Edits of Significance

- Added two injections to Step
- Updated CAB LA risk language



Other Noteworthy Edits

- Clarified pregnancy activities during all steps
- Simplified consent form
- Included lab section and HIV testing algorithm



Protocol v5: Two More Injections



Appendix VIII: Schedule of Evaluations for Step 6-Procedures for Participants on Maintenance Doses of CAB LA weeks 49-96 (or Weeks 49-112)

Time in Step 6 **	Week 56	Wee k 64	Week 72	Week 80	Week 88	Week 96≝	Week 104	Week 112
ADMINISTRATIVE PROCEDURES								
Informed Consent	Х						<u>X</u> ⁸	
Locator information	X	X	X	Х	Х	X	X	<u>X</u>
Acceptability assessment			х			X		
Behavioral assessment			Х			х		<u>X</u>
HIV prevention counseling	Х	Х	Х	Х	Х	х	X	<u>X</u>
Offer condoms per local SOC	Х	Х	Х	Х	Х	х	X	<u>X</u>
CLINICAL EVALUATIONS & PROCEDU	RES						•	
Medical history, concomitant medications, targeted physical exam (with pulse, BP, weight and BMI calculated at each visit)	х	х	х	х	х	х	X	X
Blood collection	X	х	Х	Х	Х	Х	X	<u>X</u>
Urine collection ¹	Х	Х	Х	Х	Х	X	X	X
Vaginal swab collection ²			Х			X		X
Adherence counseling ³	Х	х	х	Х	Х	Х	X	<u>X</u>
Administer CAB LA	х	х	х	х	х	Х	X	X
LOCAL LABORATORY EVALUATIONS & PROCEDURES								
HIV testing ⁴	X	X	X	X	X	X	X	X
HIV viral load testing ⁵	X	X	X	X	X	X	X	<u>X</u>
Pregnancy testing, only if indicated ¹	X	X	X	X	X	X	X	<u>X</u>
Chemistry testing ⁹						X		<u>X</u>
Liver function testing ⁶						X		<u>X</u>
Syphilis testing			X			X		<u>X</u>
GC/CT and TV testing ²			X			X		<u>X</u>
Plasma storage ^{7,8}	X	X	Х	Х	Х	X	X	<u>X</u>
DBS storage ⁸	X	X	X	X	X	X	X	<u>X</u>



Table Footnote:

At Week 96, site staff must determine whether the PPT can access CAB LA locally, outside of the trial. If the PPT has access to CAB LA, Week 96 will be the final visit. If local access to CAB LA is delayed for any reason, offer the PPT up to two additional injections on the study (Weeks 104 and 112).



Protocol v5: CAB LA Risk Language Update

- Allergic Reaction
- Suicide







Protocol v5: Pregnant PPT Data Collection





The protocol now includes text explaining the data to be collected for all PPTs:

- Ultrasound at 12 weeks
- At birth
- At 48 weeks post delivery
- All SAEs

Protocol v5: Remaining Updates



Simplified consent form

. Why is the research study being updated?

The team is updating the research study to make two changes. Those changes are highlighted in grey so that you can easily see them in this document. The first change is to add new CAB LA side effects. Those side effects are explained later in this document and the team at your study site will talk with you about them. The second change being made is to add two more CAB LA injections at the end of the second open label period for any participants who cannot yet access CAB LA locally.

Included lab section and HIV testing algorithm

SECTION 9.0 ((MODIFIED FROM THE MAIN PROTOCOL)

Laboratory procedures are described below and in the SSP for any participant who has a reactive or positive HIV test after Enrollment.

9.1 Local Laboratory Specimens

The following types of tests will be performed at the local laboratory:

- HIV testing (see SSP Manual)
- Pregnancy testing (see below)
- HBV and HCV testing to include HBsAg, HBsAb, HBcAb (total), HCV antibody tests
- · Complete blood count (CBC) with differential
- Chemistry testing (blood-urea nitrogen (BUN) or urea, creatinine, CPK, glucose, calcium, phosphorous, amylase, lipase)
- LFTs (AST, ALT, TBili, alkaline phosphatase)
- Fasting lipid profile (total cholesterol, high-density lipoprotein (HDL), triglycerides, low-density lipoprotein (LDL)) calculated or measured
- Syphilis serologic testing



Protocol v5: NIH Review Timeline



Regulatory Review

10 working day review

Medical Officer Review

10 working day review

Regulatory Chief Sign-off

5 working days